Coexisting emphysema may be an important phenotype in patients with fibrotic interstitial lung disease (ILD), tied to ...
The 9 companies—Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and ...
Colborn noted CMS estimates that approximately 13 million individuals could be eligible for GLP-1 therapy for weight loss ...
In "Why FACT Accreditation Still Matters for CAR T-Cell Therapy," the discussion turns to why FACT accreditation for CAR T-cell therapy access has held up over 25 years.
New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients. This episode, "New ...
FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations. One-year results from the ...
Selinexor achieved a 35% or greater spleen volume reduction in 17% of patients at week 24, and in 23% at any point during ...
Data show most older adults with newly diagnosed AML expect stable or improving physical function, while oncologists ...
In the Columbia cohort, the adjusted odds of fibrosis-like abnormalities per natural log-fold increase in CC16 ranged from 5.0 (95% CI, 1.6-20.7) to 16.0 (95% CI, 4.1-111) across 9 cross-sectional and ...
Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options ...
Individuals with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS), across 4 ...
Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said. Nde framed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results